# An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

> **NCT00327470** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 288 (actual)

## Conditions studied

- Age Related Macular Degeneration (AMD)
- Macular Degeneration
- Choroidal Neovascularization (CNV)

## Interventions

- **DRUG:** Pegaptanib Sodium 0.3 mg

## Key facts

- **NCT ID:** NCT00327470
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 288 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327470, "An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00327470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*